Antineoplastic properties of bacteriocins revisiting potential active agents

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 4, 2008, Pages 399-404

  Cornut, Gilbert ^a   Fortin, Claude ^a   Soulières, Denis ^b  

^a Departments of Microbiology   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antimicrobial peptide; Bacteriocin; Cancer; Prevention

Indexed keywords

BACTERIOCIN; BLEOMYCIN; CELECOXIB; COLICIN; COLICIN A; COLICIN E1; COLICIN E3; COLICIN U; MICROCIN B17; MICROCIN E492; MICROCIN J25; PEDIOCIN; PEDIOCIN PA1; PYOCIN; PYOCIN S2; QUINOLONE; SMEGMATOCIN; UNCLASSIFIED DRUG; VEROTOXIN 1; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BACTERICIDAL ACTIVITY; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; COLON CANCER; COLON POLYP; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG PURIFICATION; DRUG SCREENING; DRUG STRUCTURE; GERM CELL TUMOR; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; MAMMAL CELL; NONHUMAN; PRECANCER; REVIEW; ANIMAL; NEOPLASM;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIOCINS; HUMANS; NEOPLASMS;

EID: 55449099992     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815e456d     Document Type: Review

References (68)

1. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother. 2006;7:653-663.
2. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs. 2006;15: 933-946.
3. Klaenhammer TR. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev. 1993;12:39-85.
4. Tagg JR. Bacteriocins of Gram-positive bacteria; an opinion regarding their nature, nomenclature, and numbers. In: James R, Lazdunski C, Pattus F, eds. Bacteriocins, Microcins and Lantibiotics, Berlin: Springer, 1992:33-35.
5. Gillor O, Nigro LM, Riley MA. Genetically engineered bacteriocins and their potential as the next generation of antimicrobials. Curr Pharm Des. 2005;11:1067-1075.
6. Kirkup BC Jr. Bacteriocins as oral and gastrointestinal antibiotics: theoretical considerations, applied research, and practical applications. Curr Med Chem. 2006;13:3335-3350.
7. Nascimento JS, Ceotto H, Nascimento SB, et al. Bacteriocins as alternative agents for control of multiresistant staphylococcal strains. Lett Appl Microbiol. 2006;42:215-221.
8. Farkas-Himsley H, Hill R, Rosen B, et al. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci USA. 1995;92:6996-7000.
9. Nes IF, Holo H. Class II antimicrobial peptides from lactic acid bacteria. Biopolymers. 2000;55:50-61.
10. Chatterjee C, Paul M, Xie L, et al. Biosynthesis and mode of action of lantibiotics. Chem Rev. 2005;105:633-684.
11. Bauer R, Dicks LM. Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol. 2005;101:201-216.
12. Hechard Y, Sahl HG. Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie. 2002;84:545-557.
13. Moll GN, Konings WN, Driessen AJ. Bacteriocins: mechanism of membrane insertion and pore formation. Antonie Van Leeuwenhoek. 1999;76:185-198.
14. McAuliffe O, Ross RP, Hill C. Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol Rev. 2001;25:285-308.
15. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005;3:777-788.
16. Wils J, O'Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol. 2001;12:13-22.
17. Souglakos J, Vardakis N, Androulakis N, et al. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. J BUON. 2005;10:47-52.
18. Fumarola D. Bacteriocins as cytotoxic agents against tumors: the role of possible contaminants. Boll Ist Sieroter Milan. 1978;57:101-102.
19. Farkas-Himsley H, Cheung R. Bacterial proteinaceous products (bacteriocins) as cytotoxic agents of neoplasia. Cancer Res. 1976;36:3561-3567.
20. Hill RP, Farkas-Himsley H. Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. Cancer Res. 1991; 51:1359-1365.
21. Farkas-Himsley H, Zhang YS, Yuan M, et al. Partially purified bacteriocin kills malignant cells by apoptosis: programmed cell death. Cell Mol Biol (Noisy-le-grand). 1992;38:643-651.
22. Saito H, Watanabe T. Effect of a bacteriocin produced by Mycobacterium smegmatis on growth of cultured tumor and normal cells. Cancer Res. 1979;39:5114-5117.
23. Saito H, Watanabe T. Effects of a bacteriocin from Mycobacterium smegmatis on BALB/3T3 and simian virus 40-transformed BALB/c mouse cells. Microbiol Immunol. 1981;25:13-22.
24. Saito H, Tomioka H, Watanabe T, et al. Mycobacteriocins produced by rapidly growing mycobacteria are Tween-hydrolyzing esterases. J Bacteriol. 1983;153:1294-300.
25. de Lorenzo V. Isolation and characterization of microcin E492 from Klebsiella pneumoniae. Arch Microbiol. 1984;139:72-75.
26. Hetz C, Bono MR, Barros LF, et al. Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc Natl Acad Sci USA. 2002;99:2696-2701.
27. Lally ET, Hill RB, Kieba IR, et al. The interaction between RTX toxins and target cells. Trends Microbiol. 1999;7:356-361.
28. Vizan JL, Hernandez-Chico C, del Castillo I, et al. The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase. EMBO J. 1991;10:467-476.
29. Heddle JG, Blance SJ, Zamble DB, et al. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. J Mol Biol. 2001;307:1223-1234.
30. Delgado MA, Rintoul MR, Farias RN, et al. Escherichia coli RNA polymerase is the target of the cyclopeptide antibiotic microcin J25. J Bacteriol. 2001;183:4543-4550.
31. Smith AW, Hirst PH, Hughes K, et al. The pyocin Sa receptor of Pseudomonas aeruginosa is associated with ferripyoverdin uptake. J Bacteriol. 1992;174:4847-4849.
32. Michel-Briand Y, Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie. 2002;84:499-510.
33. Sano Y, Kobayashi M, Kageyama M. Functional domains of S-type pyocins deduced from chimeric molecules. J Bacteriol. 1993;175:6179-6185.
34. Baysse C, Meyer JM, Plesiat P, et al. Uptake of pyocin S3 occurs through the outer membrane ferripyoverdine type II receptor of Pseudomonas aeruginosa. J Bacteriol. 1999;181:3849-3851.
35. Farkas-Himsley H, Musclow CE. Bacteriocin receptors on malignant mammalian cells: are they transferrin receptors? Cell Mol Biol. 1986; 32:607-617.
36. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603:31-46.
37. Abdi-Ali A, Worobec EA, Deezagi A, et al. Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. Can J Microbiol. 2004;50:375-381.
38. Rodriguez JM, Martinez MI, Kok J. Pediocin PA-1, a wide-spectrum bacteriocin from lactic acid bacteria. Crit Rev Food Sci Nutr. 2002;42: 91-121.
39. Beaulieu L. Production, purification et caractérisation de la pédiocine PA-1 naturelle et de ses formes recombiantes: contribution à la mise en evidence d'une nouvelle activité biologique. Université Laval, Québec; 2004.
40. Lancaster LE, Wintermeyer W, Rodnina MV. Colicins and their potential in cancer treatment. Blood Cells Mol Dis. 2007;38:15-18.
41. Chumchalova J, Smarda J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha). 2003;48:111-115.
42. Smarda J, Obdrzalek V, Taborsky I, et al. The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells. Folia Microbiol (Praha). 1978;23:272-277.
43. Smarda J, Keprtova J. Cytotoxic effects of colicins E1-E5 and K on hamster fibroblasts. Folia Microbiol (Praha). 1987;32:133-136.
44. Smarda J, Fialova M, Smarda J Jr. Cytotoxic effects of colicins E1 and E3 on v-myb-transformed chicken monoblasts. Folia Biol (Praha). 2001;47:11-13.
45. Fuska J, Fuskova A, Smarda J, et al. Effect of colicin E3 on leukemia cells P388 in vitro. Experientia. 1979;35:406-407.
46. Ray B. Fundamental Food Microbiology. Boca Raton, FL: CRC Press; 2004.
47. Johnsen L, Fimland G, Eijsink V, et al. Engineering increased stability in the antimicrobial peptide pediocin PA-1. Appl Environ Microbiol. 2000;66:4798-4802.
48. Rollema HS, Kuipers OP, Both P, et al. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol. 1995;61:2873-2878.
49. Lee KH. Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries. Curr Pharm Des. 2002; 8:795-813.
50. Borghouts C, Kunz C, Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 2005;11: 713-726.
51. Tsugu H, Onishi H, Fukushima T, et al. Anti-tumor activity of de novo designed small globular protein (SGP) in vivo. Anticancer Res. 2006; 26:4043-4046.
52. Delves-Broughton J, Blackburn P, Evans RJ, et al. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek. 1996;69:193-202.
53. Parente E, Ricciardi A. Production, recovery and purification of bacteriocins from lactic acid bacteria. Appl Microbiol Biotechnol. 1999;52: 628-638.
54. Rodriguez JM, Martinez MI, Horn N, et al. Heterologous production of bacteriocins by lactic acid bacteria. Int J Food Microbiol. 2003;80:101-116.
55. Gibbs GM, Davidson BE, Hillier AJ. Novel expression system for large-scale production and purification of recombinant class IIa bacteriocins and its application to piscicolin 126. Appl Environ Microbiol. 2004;70:3292-3297.
56. Heavey PM, Rowland IR. Microbial-gut interactions in health and disease. Gastrointestinal cancer. Best Pract Res Clin Gastroenterol. 2004;18:323-336.
57. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol. 2006;12:6741-6746.
58. Collado MC, Hernandez M, Sanz Y. Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. J Food Prot. 2005;68:1034-1040.
59. Millette M, Dupont C, Archambault D, et al. Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J Appl Microbiol. 2007;102:274-282.
60. Kang JH, Lee MS. Characterization of a bacteriocin produced by Enterococcus faecium GM-1 isolated from an infant. J Appl Microbiol. 2005;98:1169-1176.
61. Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. Methods Mol Biol. 2004;268:491-502.
62. Smarda J, Obdrzalek V. Incidence of colicinogenic strains among human Escherichia coli. J Basic Microbiol. 2001;41:367-374.
63. Rodriguez E, Martinez MI, Medina M, et al. Detection of enterocin AS-48-producing dairy enterococci by dot-blot and colony hybridization. J Dairy Res. 1998;65:143-148.
64. Horz HP, Meinelt A, Houben B, et al. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007;22:126-130.
65. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 2005;41: 1911-1922.
66. Swamy MV, Patlolla JM, Steele VE, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006; 66:7370-7377.
67. Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut. 2002;50:1-5.
68. El-Salhy M, Hilding L, Royson H, et al. Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. Int J Oncol. 2005;27:687-691.